bioAffinity Technologies
BIAF
6 hedge funds and large institutions have $140K invested in bioAffinity Technologies in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
4,897% more capital inflows, than outflows
Capital inflows: $38.1K | Capital outflows: $762
20% more funds holding
Funds holding: 5 → 6 (+1)
0.14% more ownership
Funds ownership: 1.13% → 1.27% (+0.14%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$33.5K |
| 2 |
Tower Research Capital (TRC)
New York
|
+$4.57K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$762 |
BIAF Hedge Fund Activity: Q3 2023 in Review
6 of the 6,316 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAF) for Q3 2023, worth a combined $140K — down 21% from $177K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new BIAF positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $33.5K. The largest seller was Two Sigma Investments, cutting an estimated $762.
- 6 institutional investors held bioAffinity Technologies (BIAF) as of Q3 2023, up from 5 in Q2 2023.
- Funds reported $140K of bioAffinity Technologies stock for Q3 2023, down 21% quarter-over-quarter.
- 1 fund opened new bioAffinity Technologies positions in Q3 2023 and 0 closed out, a net change of +1 holder.
- The largest bioAffinity Technologies buyer in Q3 2023 was Vanguard Group, an estimated $33.5K added.
- The largest bioAffinity Technologies seller in Q3 2023 was Two Sigma Investments, an estimated $762 sold.
Based on aggregated 13F filings for Q3 2023.